


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A method of increasing the sensitivity of cancer cells or a tumour to a chemotherapeutic agent by contacting said cells or tumour with an isoflavonoid compound of formula 12:




wherein the cancer is ovarian, pancreatic or prostate cancer, and
the chemotherapeutic agent is cisplatin, or
the cancer is ovarian cancer, and
the chemotherapeutic agent is carboplatin, or
the cancer is ovarian or prostate cancer, and
the chemotherapeutic agent is paclitaxel, or
the cancer is ovarian or pancreatic cancer, and
the chemotherapeutic agent is gemcitabine or doxorubicin.

2. (previously presented): A method of claim 1, wherein prior to the contacting, the cancer cells or tumour were/was not sensitive to the chemotherapeutic agent.

3. (previously presented): A method of claim 1, wherein the compound of formula 12 is administered to a subject in need of such treatment.

4. (currently amended): A combination therapy for the treatment ~~or prophylaxis~~ of cancer comprising administering to a subject a therapeutically effective amount of a compound of formula 12 and a chemotherapeutic agent:



wherein the cancer is ovarian, pancreatic or prostate cancer, and

the chemotherapeutic agent is cisplatin, or

the cancer is ovarian cancer, and

the chemotherapeutic agent is carboplatin, or

the cancer is ovarian or prostate cancer, and

the chemotherapeutic agent is paclitaxel, or

the cancer is ovarian or pancreatic cancer, and

the chemotherapeutic agent is gemcitabine or doxorubicin.

5.-7. (canceled).


8. (previously presented): A method of claim 4, wherein the administration of the compound of formula 12 precedes the administration of the chemotherapeutic agent.

9. (previously presented): A method of claim 4, wherein the administration of the compound of formula 12 and the chemotherapeutic agent is simultaneous.

10. (previously presented): A method claim 4, wherein the combination therapy follows observed resistance by cancer cells or tumour to the chemotherapeutic agent.

11.-22. (canceled).

23. (previously presented): A pharmaceutical composition comprising a compound of formula 12 and a chemotherapeutic agent:



AMENDMENT UNDER 37 C.F.R. § 1.114(c)
U.S. Application No.: 10/530,176

Attorney Docket No.: Q86664

wherein the chemotherapeutic agent is cisplatin, carboplatin, paclitaxel, gemcitabine or doxorubicins.

24.-28. (Canceled).